Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB to present new data on Cimzia at ACG annual scientific meeting

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

U-M researchers to study new approach in halting downward spiral of diabetes

U-M researchers to study new approach in halting downward spiral of diabetes

QUT program assists cancer survivors in self-managing their health, emotional concerns

QUT program assists cancer survivors in self-managing their health, emotional concerns

AANEM Foundation strengthens and expands research initiatives

AANEM Foundation strengthens and expands research initiatives

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

New research has potential to alleviate side effects of cancer treatments

New research has potential to alleviate side effects of cancer treatments

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

NeuroMetrix second quarter total revenues decrease to $2.6 million

NeuroMetrix second quarter total revenues decrease to $2.6 million

Essential criteria for clinical diagnosis of restless legs syndrome

Essential criteria for clinical diagnosis of restless legs syndrome

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy